Monopar Therapeutics Inc
NASDAQ:MNPR

Watchlist Manager
Monopar Therapeutics Inc Logo
Monopar Therapeutics Inc
NASDAQ:MNPR
Watchlist
Price: 25.82 USD 8.53% Market Closed
Market Cap: 136.3m USD
Have any thoughts about
Monopar Therapeutics Inc?
Write Note

Monopar Therapeutics Inc
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Monopar Therapeutics Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Monopar Therapeutics Inc
NASDAQ:MNPR
Net Income (Common)
-$6.5m
CAGR 3-Years
9%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Net Income (Common)
$5.1B
CAGR 3-Years
-12%
CAGR 5-Years
9%
CAGR 10-Years
3%
Gilead Sciences Inc
NASDAQ:GILD
Net Income (Common)
$126m
CAGR 3-Years
-74%
CAGR 5-Years
-46%
CAGR 10-Years
-35%
Amgen Inc
NASDAQ:AMGN
Net Income (Common)
$4.2B
CAGR 3-Years
-9%
CAGR 5-Years
-12%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Income (Common)
-$479.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
1%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Income (Common)
$4.7B
CAGR 3-Years
-13%
CAGR 5-Years
17%
CAGR 10-Years
30%
No Stocks Found

Monopar Therapeutics Inc
Glance View

Market Cap
136.3m USD
Industry
Biotechnology

Monopar Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Wilmette, Illinois and currently employs 9 full-time employees. The company went IPO on 2019-12-19. The firm is primarily focused on developing therapeutics designed for cancer patients. Its product pipeline includes Validive, camsirubicin, MNPR-101, and MNPR-202. The Validive is a first-in-class mucoadhesive buccal tablet for the prevention of radiation induced severe oral mucositis (SOM) in oropharyngeal cancer patients. Its camsirubicin is a clinical stage topoisomerase II-alpha selective novel analog of doxorubicin engineered specifically to retain anticancer activity while minimizing toxic effects on the heart. Its MNPR-101 is a humanized monoclonal antibody designed to bind a specific cell surface receptor found on cancer cells, the urokinase plasminogen activator receptor (uPAR), and to interrupt several pathways required for tumor growth and progression. The MNPR-202 is an early stage camsirubicin analog for various cancers.

MNPR Intrinsic Value
18.25 USD
Overvaluation 29%
Intrinsic Value
Price

See Also

What is Monopar Therapeutics Inc's Net Income (Common)?
Net Income (Common)
-6.5m USD

Based on the financial report for Sep 30, 2024, Monopar Therapeutics Inc's Net Income (Common) amounts to -6.5m USD.

What is Monopar Therapeutics Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-11%

Over the last year, the Net Income (Common) growth was 32%. The average annual Net Income (Common) growth rates for Monopar Therapeutics Inc have been 9% over the past three years , -11% over the past five years .

Back to Top